Julia E. McGuinness

Julia E. McGuinness

Auto-generated profile, based on publicly available information

Julia E. McGuinness

Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, New York

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2020 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
JMJulia E. McGuinness
Julia E. McGuinness
KKKevin Kalinsky
Kevin Kalinsky
Metastatic triple-negative breast cancers (mTNBC) are characterized by aggressive behavior and worse clinical outcomes than other breast cancer subtypes, as well as poor response to cytotoxic chemo...

1 June 2019 in Cancer Genetics
Verified
Journal Article
Closed access
JMJulia E. McGuinness
Julia E. McGuinness
MTMeghna S. Trivedi
Meghna S. Trivedi
TSThomas Silverman
Thomas Silverman
AMAwilda Marte
Awilda Marte
JMJennie Mata
Jennie Mata
KCKatherine D. Crew
Katherine D. Crew

14 November 2021 in Clinical Breast Cancer
Verified
Journal Article
Open access
MWMargaux Wooster
Margaux Wooster
JMJulia E. McGuinness
Julia E. McGuinness
KFKathleen M. Fenn
Kathleen M. Fenn
VSVeena M. Singh
Veena M. Singh
LFLauren E. Franks
Lauren E. Franks
KKKevin Kalinsky
Kevin Kalinsky
Leptomeningeal metastasis (LM) is a devastating complication of metastatic breast cancer; however, diagnosis is limited by low sensitivity of cerebrospinal fluid cytopathology. This study evaluates a novel assay, CNSide™, and demonstrates 100% sensitivity for LM and additionally, capacity for receptor assessment and mutation identification. CNSide™ may be a viable platform to detect LM, with potential use as a diagnostic tool.

9 June 2022 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
KCKatherine D. Crew
Katherine D. Crew
GBGauri Bhatkhande
Gauri Bhatkhande
TSThomas Silverman
Thomas Silverman
JAJacquelyn Amenta
Jacquelyn Amenta
TJTarsha Jones
Tarsha Jones
RKRita Kukafka
Rita Kukafka
Significant underutilization of breast cancer chemoprevention remains, despite guidelines stating that physicians should recommend chemoprevention with antiestrogen therapy to high-risk women. We randomized women, ages 35 to 75 years, who met high-risk criteria for breast cancer, without a personal history of breast cancer or prior chemoprevention use, to standard educational materials alone or combined with a web-based decision aid. All healthcare providers, including primary care providers and breast specialists, were given access to a web-based decision support tool. The primary endpoint was chemoprevention uptake at 6 months. Secondary outcomes included decision antecedents (perceived breast cancer risk/worry, chemoprevention knowledge, self-efficacy) and decision quality (decision conflict, chemoprevention informed choice) based upon patient surveys administered at baseline, 1 and 6 months after randomization. Among 282 evaluable high-risk women enrolled from November 2016 to March 2020, mean age was 57 years (SD, 9.9) and mean 5-year invasive breast cancer risk was 2.98% (SD, 1.42). There was no significant difference in chemoprevention uptake at 6 months between the intervention and control groups (2.1% vs. 3.5%). Comparing the intervention and control arms at 1 month, there were significant differences among high-risk women in accurate breast cancer risk perceptions (56% vs. 39%, P = 0.017), adequate chemoprevention knowledge (49% vs. 27%, P < 0.001), mean decision conflict (34.0 vs. 47.0, P < 0.001), and informed choice (41% vs. 23%, P = 0.003). These differences were no longer significant at 6 months. Although our decision support tools did not result in a significant increase in chemoprevention uptake, we did observe improvements in decision antecedents and decision quality measures. Prevention Relevance: In this randomized controlled trial of decision support for 300 high-risk women and 50 healthcare providers, we did not observe a significant increase in chemoprevention uptake, which remained low at under 5%. However, these decision support tools may increase knowledge and informed choice about breast cancer chemoprevention.

27 October 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
VRVicky Ro
Vicky Ro
JMJulia E. McGuinness
Julia E. McGuinness
BGBoya Guo
Boya Guo
MTMeghna S. Trivedi
Meghna S. Trivedi
TJTarsha Jones
Tarsha Jones
KCKatherine D. Crew
Katherine D. Crew
PURPOSE: Increasing usage of multigene panel testing has identified more patients with pathogenic or likely pathogenic (P or LP) variants in low-moderate penetrance genes or variants of uncertain significance (VUS). Our study evaluates the association between genetic test results and contralateral prophylactic mastectomy (CPM) among patients with breast cancer. METHODS: We conducted a retrospective cohort study among women diagnosed with unilateral stage 0-III breast cancer between 2013 and 2020 who underwent genetic testing. We examined whether genetic test results were associated with CPM using multivariable logistic regression models. RESULTS: Among 707 racially or ethnically diverse women, most had benign or likely benign (B or LB) variants, whereas 12.5% had P or LP and 17.9% had VUS. Racial or ethnic minorities were twice as likely to receive VUS. Patients with P or LP variants had higher CPM rates than VUS or B or LB (64.8% v 25.8% v 25.9%), and highest among women with P or LP variants in high-penetrance genes (74.6%). On multivariable analysis, P or LP compared with B or LB variants were significantly associated with CPM (odds ratio = 4.24; 95% CI, 2.48 to 7.26). CONCLUSION: Women with P or LP variants on genetic testing were over four times more likely to undergo CPM than B or LB. Those with VUS had similar CPM rates as B or LB. Our findings suggest appropriate genetic counseling and communication of cancer risk to multiethnic breast cancer survivors.

29 March 2022 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
JMJulia E. McGuinness
Julia E. McGuinness
GBGauri Bhatkhande
Gauri Bhatkhande
JAJacquelyn Amenta
Jacquelyn Amenta
TSThomas Silverman
Thomas Silverman
JMJennie Mata
Jennie Mata
KCKatherine D. Crew
Katherine D. Crew
We evaluated strategies to identify and recruit a racially/ethnically diverse cohort of women at high-risk for breast cancer to a randomized controlled trial (RCT). We enrolled 300 high-risk women and 50 healthcare providers to a RCT of standard educational materials alone or in combination with web-based decision support tools. We implemented five strategies to identify high-risk women: (i) recruitment among patients previously enrolled in a study evaluating breast cancer risk; (ii) automated breast cancer risk calculation using information extracted from the electronic health record (EHR); (iii) identification of women with atypical hyperplasia or lobular carcinoma in situ (LCIS) using International Classification of Diseases (ICD)-9/10 diagnostic codes; (iv) clinical encounters with enrolled healthcare providers; (v) recruitment flyers/online resources. Breast cancer risk was calculated using either the Gail or Breast Cancer Surveillance Consortium (BCSC) models. We identified 6,229 high-risk women and contacted 3,459 (56%), of whom 17.2% were identified from prior study cohort, 37.5% through EHR risk information, 14.8% with atypical hyperplasia/LCIS, 29.0% by clinical encounters, and 1.5% through recruitment flyers. Women from the different recruitment sources varied by age and 5-year invasive breast cancer risk. Of 300 enrolled high-risk women, 44.7% came from clinical encounters and 27.3% from prior study cohort. Comparing enrolled with not-enrolled participants, there were significant differences in mean age (57.2 vs. 59.1 years), proportion of non-Whites (41.5% vs. 54.8%), and mean 5-year breast cancer risk (3.0% vs. 2.3%). We identified and successfully recruited diverse high-risk women from multiple sources. These strategies may be implemented in future breast cancer chemoprevention trials. Prevention Relevance: We describe five strategies to identify and successfully recruit a large cohort of racially/ethnically diverse high-risk women from multiple sources to a randomized controlled trial evaluating interventions to increase chemoprevention uptake. Findings could inform recruitment efforts for future breast cancer prevention trials to increase recruitment yield of high-risk women.